Goserelin

(Zoladex®)

Goserelin

Drug updated on 11/4/2024

Dosage FormImplant (subcutaneous; 10.8 mg)
Drug ClassGonadotropin-releasing hormone agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate
  • Indicated for use as palliative treatment of advanced carcinoma of the prostate.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • Mammographic Breast Density (MBD) Reduction in Premenopausal Women: Goserelin achieved a 2.7% reduction in MBD among premenopausal women without a breast cancer history, with MBD returning to baseline post-treatment. Comparatively, tamoxifen and leuprolide acetate showed higher MBD reductions (13.4% and 8.9%, respectively), while nonhormonal interventions like vitamin D and isoflavones showed no reduction.
  • Uterine Fibroids Treatment in Premenopausal Women: Goserelin was less effective in reducing abnormal uterine bleeding than oral progestogens (dienogest and desogestrel), with no significant effect on fibroid size observed.
  • Safety in Prostate Cancer Treatment: Goserelin, compared to GnRH (gonadotropin-releasing hormone) antagonists (degarelix and relugolix), demonstrated a higher incidence of adverse cardiovascular events, with pooled risk ratios significantly favoring GnRH antagonists for lower cardiovascular events (0.57), cardiovascular death (0.49), and all-cause mortality (0.48).
  • Uterine Fibroids: Goserelin was associated with vasomotor symptoms, such as hot flashes, in 55% of users, while oral progestogens (dienogest and desogestrel) did not show such adverse events.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Zoladex (goserelin) Prescribing Information.2023TerSera Therapeutics LLC, Deerfield, IL

Systematic Reviews / Meta-Analyses